Chinese cancer detection firm Burning Rock eyes US IPO

By Jonathan Breen
25 May 2020

Burning Rock Biotech is planning to float on Nasdaq for as much as $100m.

The Guangzhou, China-based company, submitted draft listing documents with the US regulator on May 22.

Burning Rock has appointed underwriters Bank of America, Cowen and Co and Morgan Stanley to lead the deal. CMB International and Tiger Brokers are also the underwriters.

The issuer produces therapies for precision ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial